Psychiatric Ratings using Intermediate Stratified Markers: providing quantitative biological measures to facilitate the discovery and development of new treatments for social and cognitive deficits in AD, SZ, and MD
PRISM logo


Start Date
End Date
IMI2 - Call 3
Grant agreement number

Type of Action: 
RIA (Research and Innovation Action)

IMI Funding
8 080 000
EFPIA in kind
9 019 551
Total Cost17 099 552


Social withdrawal is a common early symptom of many neurological disorders, including schizophrenia, Alzheimer’s disease, and major depressive disorder. However, the underlying, biological causes of this symptom are still poorly understood and may differ from one disease to another. The PRISM project will carry out a range of tests, including blood tests, brain scans, and measures of behaviour, on patients with these all too common diseases in a bid to determine which biological parameters correlate with specific clinical symptoms, like social withdrawal. The hope is that the project’s findings will shed new light on the causes of mental illness and their symptoms and facilitate the development of much-needed new treatments.

Achievements & News

PRISM clinical study on social withdrawal gets underway
September 2017

The PRISM project’s clinical study on the biological underpinnings of social withdrawal in Alzheimer’s disease and schizophrenia is now officially underway, as the first patients have had their first clinical visits.### Social withdrawal is a common early symptom of both Alzheimer’s disease and schizophrenia. However, we do not know if the underlying causes of social withdrawal in the two diseases are the same or different. In this study, PRISM scientists will study over 200 people, including people with suspected Alzheimer’s disease, people with schizophrenia, and healthy people (the control group). Participants with the diseases under study will include people who show signs of social withdrawal as well as people who do not. Participants will undergo a range of tests, including brain scans, blood tests and questionnaires. They will also be offered the opportunity to use a smartphone app called BeHapp that measures people’s sociability and social exploration in their daily lives. ‘The ability to precisely link symptoms to underlying neurobiology would not only facilitate the development of better treatments, it would also allow physicians to provide patients and relatives with a better understanding of the complexities and management of their illness,’ said the project. ‘Moreover, there is a growing realisation that psychiatric and neurodegenerative disorders overlap by much more than previously thought, and that they may better be described as domains of trans-diagnostic traits rather than separable categories.’

Participants Show participants on map

EFPIA companies
  • Boehringer Ingelheim International GmbH, Ingelheim, Germany
  • Eli Lilly and Company Ltd, Basingstoke, United Kingdom
  • F. Hoffmann-La Roche Ltd, Basel, Switzerland
  • Janssen Pharmaceutica NV, Beerse, Belgium
  • Novartis Pharma AG, Basel, Switzerland
  • Pfizer Limited, Sandwich, Kent , United Kingdom
  • Takeda Development Centre Europe Ltd., London, United Kingdom
Universities, research organisations, public bodies, non-profit groups
  • Academisch Ziekenhuis Leiden - Leids Universitair Centrum, Leiden, Netherlands
  • Alma Mater Studiorum - Università di Bologna, Bologna, Italy
  • Centro De Investigacion Biomedica En Red, Madrid, Spain
  • Erasmus Universitair Medisch Centrum Rotterdam, Rotterdam, Netherlands
  • Rijksuniversiteit Groningen, Groningen, Netherlands
  • STICHTING VUmc, Amsterdam, Netherlands
  • Stichting Buro ECNP , Utrecht, Netherlands
  • Stichting Katholieke Universiteit / Radboud university medical center, Nijmegen, Netherlands
  • The University of Exeter, Exeter, United Kingdom
  • Universitair Medisch Centrum Utrecht , Utrecht, Netherlands
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
  • Biotrial SAS, Rennes, France
  • Concentris Research Management GmbH, Fürstenfeldbruck, Germany
  • Drug Target Id BV, Nijmegen, Netherlands
  • P1vital Limited, Wallingford, United Kingdom
  • SBGNeuro Limited, Thame, United Kingdom
Patient organisations
  • European Federation of Associations of Families of People with Mental Illness, Leuven, Belgium
Third parties
  • P1vital Products LTD, Wallingford, United Kingdom


Project coordinator
Martien Kas
Industry project leader
Hugh Marston
Eli & Lilly